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ABSTRACT 
 
Introduction 
 
Against the high background rate of HIV among our antenatal clinic attendees, 30.3% in 
Gauteng in 2007, and the importance of cancer of the cervix as a health issue; this study was 
undertaken to determine the rate of abnormality found in cervical smears performed on HIV 
positive women attending the postnatal clinic at Johannesburg Hospital. The degree of 
abnormality and where possible its management, was reviewed.  Secondly it was determined 
whether the immune status, namely the WHO clinical stage, CD4 cell count and viral load, 
correlated with the Pap smear results. Lastly patients were also analyzed according to the 
treatment received for HIV and their Pap smear results. 
 
Patients and Methods 
 
The study is a retrospective record review. All the patients who attended the postnatal clinic 
(PNC) between October 2005 and the end of July 2006, who had a Pap smear, were included. 
Follow-up test results were collected to the end of June 2007. A total of 324 patients attended the 
clinic in the study time period, of which 248 (76.5%) had a Pap smear done and 76 (23.5%) did 
not. 
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Results 
 
The main results of interest were as follows – 131 patients (52.8%) had normal Pap smears, 
64(25.8%) had LGSIL, 32 (12.9%) had HGSIL, 10 (4.0%) had ASCUS and 11 (4.4%) had Pap 
smears that could not be classified. In total 47.2% of the Pap smears were abnormal.  There was 
one case of malignancy developing after an abnormal Pap smear. Patients with abnormal Pap 
smears tended to have a lower mean CD4 cell count while the viral load and WHO Stage did not 
appear to have an impact on the final analysis of the Pap smears. 
 
Conclusion 
 
The rates of cervical abnormality in HIV sero-positive patients attending the Johannesburg 
Hospital postnatal clinic are much higher (47.2%) than would be expected in the general 
population (10%), with a significant portion requiring follow-up investigation and management. 
It is however preferable to deal with cervical cytological abnormalities comprehensively during 
the screening phase rather than trying to manage a potential increase in cervical cancer cases. 
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1.0 INTRODUCTION 
 
1.1 HIV and the antenatal population 
 
The National HIV and Syphilis Prevalence Survey 2007 by the Department of Health, using 
antenatal clinic (ANC) attendees’, estimated that 28.0% (95% CI of 26.9-29.1%) of pregnant 
women were Human Immunodeficiency Virus (HIV) sero-positive in 2007. This is an 
apparent decrease from the 30.2% and 29.1% in 2005 and 2006 respectively, although the 
sampling method is questioned. Gauteng had the third highest prevalence in 2005, - being 
32.4% (95% CI of 30.6 – 34.3) while in 2006 and 2007 it was fourth highest with a prevalence 
of 30.8% (95% CI of 29.6-32.1%) and 30.3% (95% CI of 29.9%-32.8%) respectively (1, 2, 3). 
 
1.2 Cervical cancer 
 
 The HIV epidemic co-exists with another major health concern, namely cancer of the cervix. 
The National Cancer Registry in South Africa reported in1997 that the risk of developing 
cancer of the cervix is one in 29 (age 0-74years). Black females showed the highest age 
standardised rate – 38.5 per 100 000, with a lifetime risk of one in 23 (4). Newer data was 
expected out at the end of 2008 in which the cancer incidence for 2001/2 would be reported, 
this would however not take into account the results from the private health sector that stopped 
reporting at the beginning of 2001. As of February 2009 the data was not yet available (5). The 
data from the Medical Research Council of South Africa showed that 3498 women died of 
cervical cancer in 2000, this represented 17.2% of cancer related deaths amongst women (6). 
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1.3 Cervical smears 
 
Human Papilloma Virus (HPV) is the major aetiological factor for cancer of the cervix. HPV, 
potentiated by other co-factors, including smoking, induces changes in the cervical epithelium, 
which are detectable on Papanicolaou (Pap) or cervical smear. (7) The changes are classified 
according to the 2001 Bethesda System, importantly: atypical squamous cells of undetermined 
significance (ASCUS), low-grade squamous intra-epithelial lesion (LGSIL) and high-grade 
squamous intraepithelial lesions (HGSIL) and squamous cell carcinoma (SCC). The presence 
of endocervical cells is not necessary in order to classify a Pap smear as adequate (8). In 1993 
the Centre for Disease Control (CDC) added invasive cancer of the cervix as an AIDS 
defining illness, highlighting the importance of screening programs in this high risk group (9). 
The CDC has recently suggested that a Pap smear should be done routinely at the time of HIV 
diagnosis and should be repeated six months later. If these Pap smears are normal women 
should then have yearly cervical screening. Currently in South Africa the suggested screening 
program is three Pap smears in a lifetime starting at age 30, repeated at 10- year intervals, with 
no adjustment for HIV status. This recommendation has not been fully implemented and 
screening tends to be opportunistic (4). 
 
1.4 Literature review 
 
HIV sero-positive patients have higher rates of squamous intraepithelial lesions (SIL) than 
HIV negative patients (10). The reported incidence of cervical carcinoma among HIV infected 
women is inconsistent; with some studies showing it is increased (11) and others not 
demonstrating this increase (12).  
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This may be due to the fact that patients with SIL, who are not receiving antiretroviral therapy 
(ART), partly because they are in resource poor areas, demise from HIV related disease before 
invasive cervical cancer develops (13). The prevalence though of cervical carcinoma has been 
shown to be nearly twice that of HIV negative patients (10,13), and that HIV sero-positive 
patients present nearly 10 years earlier than HIV negative patients. Furthermore if their CD4 
cell count is less than 200cells/µL at presentation they are significantly more likely to have 
advanced stage of cervical cancer (14). Importantly, HIV sero-positive patients have an 
increased infection rate with monogenic HPV (13). In a large prospective study conducted in 
Senegal, women with high risk HPV were more likely to have HGSIL or invasive carcinoma if 
they were HIV sero-positive compared to HIV sero- negative controls (15).   
 
No studies were found which reported Pap smear findings on postpartum HIV sero-positive 
women. Table 1.1 summarizes 13 studies in which Pap smear results are available for HIV 
sero-positive women. For these studies the sample size ranged from 49 – 1200 women with 
the mean or median age ranging from 28.1y to 36y, and median CD4 cell count from 160 – 
430cells/µL. Use of ART varied from all to none of the women among the nine studies that 
commented on it. The percentage of normal Pap smears was 6.7- 93.7% (13 studies) with a 
mean of 59.0%. Two studies combined their abnormal findings- with Anderson (16) finding a 
SIL rate of 26.1% and Joshi (17) 6.3%. The other 11 had a LGSIL range of 9.7- 43% and a 
HGSIL range of 2.8- 32.7%. In Zambia a squamous cell carcinoma (SCC) rate of 20 % was 
found by Parham (18). Five studies did not demonstrate ASCUS, while the range in the 
remaining eight was 0.4- 20.7%.  
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Two studies had results which were out of keeping with the other ten studies. A Zambian 
study of women attending a well HIV care clinic demonstrated higher rates of HGSIL (32.6%) 
and possible SCC (20%). The median CD4 count of 165cells/µL was surprisingly low and 
may partly account for the high percentage of severely abnormal Pap smears. In addition 
Zambia has the second highest prevalence rate of invasive cervical cancer (61.1/100 000 
women) in the world (18). In comparison a study from India, where 20% of the world’s new 
cervical cancer cases come from, only found a combined low grade and high grade SIL rate of 
6.3% with 93.7% being normal (17). The median CD4 cell count was not specified and one in 
10 women was on ART compared with 76.3% of the Zambian cohort. No explanation was 
proffered for the low rate. With such variation between studies and regions, the importance of 
having information specific to one’s own population is highlighted. 
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Table 1.1: Comparative results of Pap smears in HIV sero-positive women and selected 
variables in various studies 
 Sample 
Size 
Normal 
% 
LGSIL 
% 
HGSIL 
% 
ASCUS 
% 
Mean age 
*median  
years  
Median 
CD4 
cells/µL 
ART 
Use % 
Anderson 
USA 
2006(16)
1200 
(189) 
53.3 
(§) 
SIL Combined 
26.1      (§) 
20.7 
(§) 
34.1 430 Unknown 
Branca 
Italy 
2003(19)
89 67.4 12.4 6.7 1.1 33.46 297 100 
Chirenje 
Zimbabwe 
2002(20)
207 74.3 9.7 3.4 12.6 28.1 Not done None 
Delmas 
Europe 
2000(21)
467 75.8 21.0 2.8 0.4 31* 378 Unknown 
Denny 
S. Africa 
2008(22)
400 45 35 13 7 29.3 248 30 
Heard 
France 
1998(23)
49 31 43 26 - 33.9* 160 100 
Heard 
France 
2000(24)
307 48.2 13.7 13.3 - 32* 300 35.5 
Joshi 
India 
2005(17)
287 93.7 SIL Combined 
6.3 
- 29.1 Not 
specified 
10.1 
Levi 
Brazil 
2002(25)
255 81 12 7 - 32.4 285 80 
Lillo 
Italy 
2001(26)
163 73.4 20.2 6.2 - 33.6 Not 
specified 
83.5 
Maiman 
USA 
1998(27)
253 67.1 15.4 7.9 9.1 33.8 Not 
specified 
Unknown 
J.Moodley 
S. Africa 
2006(10)
78 50 17.9 11.5 20.5 Unknown 
 
Not done Unknown 
Parham 
Zambia 
2006(18)
150 6.7 23.3 32.7 
?SCC20 
17.3 36* 
 
165 76.3 
§- results are for the original 1200 HIV sero-positive patients, of which the 189 are a 
subgroup. 
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Patients attending the postnatal clinic were also classified clinically according to the World 
Health Organization staging system. Although the WHO guidelines were updated in 
November 2007(28), the older WHO staging criteria have been used in this study as they were 
applicable at the time patients were assessed. Cervical cancer in an HIV sero-positive patient 
stages the patient as stage 4 disease (9).  
 
In studies which have looked at immune suppression markers and their significance in the 
context of cervical pathology and HIV status,  it was found that, in general the lower the CD4 
cell count the more likely the patient was to have an abnormality(22,29), and that the lesion was 
less likely to regress (30). Patients with higher HIV viral loads were more likely to have 
oncogenic HPV  (15,19,22,26, 31, 32), an association with the degree of cervical abnormality (15,22) 
and Pap smear abnormalities that were less likely to regress (30).  
 
Smoking has been described as a risk factor in the development of genital warts and squamous 
intraepithelial lesions of the cervix which may progress to cancer of the cervix (33, 34). The 
prevalence and incidence of HPV is also increased among HIV sero-positive women (35). 
 
The advent of ART has precipitated studies looking at the effect of ART use on cervical 
dysplasia. Lillo (26) found that despite improved immunity in HIV sero-positive patients on 
ART and a rising CD4 cell count, the lesions and the persistence of oncogenic HPV were 
similar to those found in both HIV negative patients, and HIV sero-positive patients who were 
not treated with ART. However data from the Women’s Interagency HIV Study found that the 
use of highly active anti-retroviral therapy (HAART) was associated with regression and that 
the likelihood was increased with higher CD4 cell counts (36). 
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This is supported by Del Mistro’s work which emphasized the effectiveness of HAART over 
other ART regimen’s in obtaining regression, noting that for HGSIL lesions this is in 
conjunction with surgical excision (37). 
 
The management of HIV sero-positive patients with cervical pathology is not yet well defined 
in South Africa. The CDC suggests that if a Pap smear shows ASCUS, HPV typing should be 
done. If the HPV typing demonstrates an HPV with known oncogenic potential, then 
colposcopy should be performed. If no oncogenic HPV is demonstrated, then repeat Pap 
smears four to six monthly are recommended until there are three negative results. A repeat 
result of ASCUS needs colposcopy. LGSIL could be dealt with similarly, or immediately 
proceed to colposcopy. HGSIL requires colposcopy and invasive carcinoma treatment 
according to FIGO staging (11). It should be noted that koilocytosis without SIL on a Pap smear 
has on colposcopy demonstrated SIL in 49.3% of HIV sero-positive patients compared to 28% 
in HIV negative patients.  According to Moodley, this may argue against a conservative 
approach in sero-positive patients with this result (38).  Recently, a paper looking at the natural 
history of HIV sero-positive women and their Pap smear results, it was suggested that due to 
the low incidence of progression of LGSIL and ASCUS to HGSIL that after an initial 
colposcopy or normal smear follow-up can be biennial or triennial (22). 
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1.5 Objectives 
 
By way of a retrospective review, the Pap smear results in the population of women attending 
the postnatal clinic were analyzed. The objectives were to firstly determine the number of Pap 
smears done, the percentage of abnormal results and the degree of abnormality as defined in 
the 2001 Bethesda classification (8). Where possible the management of the abnormality was 
reviewed including the colposcopy results. The second was to determine whether the immune 
status, namely the WHO clinical stage, CD4 cell count and viral load, correlated with the 
patients’ Pap smear results. Lastly patients were also analyzed according to the treatment 
received for HIV and their Pap smear results.  
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2.0 METHODS 
 
2.1 Study design 
 
The study is a retrospective record review. Records of all the patients who attended the 
postnatal clinic (PNC) between October 2005 and the end of July 2006, who had a Pap smear 
performed, were included. Follow-up test results, namely serology, cytology and histology, for 
this group were collected to the end of June 2007. The research protocol was submitted and 
approved by the ethics committee, number: M060842. 
 
2.2 Study setting 
 
The PNC was established at the former Johannesburg Hospital (now the Charlotte Maxeke 
Johannesburg Academic Hospital) in October 2005 to follow up HIV infected women who 
were either initiated on HAART during pregnancy, who had not been staged clinically 
according to the World Health Organization classification during pregnancy, or who had low 
CD4 counts (<200cells/µL) but did not have the opportunity to access HAART during 
pregnancy.  
 
Patients attending the postnatal clinic were also classified clinically according to the World 
Health Organization staging system. Stage 1 patients are asymptomatic or had persistent 
generalized lymphadenopathy, and/or normal activity. Stage 2 is <10% weight loss, minor 
mucocutaneous conditions, herpes zoster in the last 5 years, recurrent upper respiratory 
infections, and/or symptomatic with normal activity. Patients in stage 3 have >10% weight 
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loss, unexplained diarrhea for more than 1 month, unexplained fever for more than 1 month, 
pulmonary TB in the last year, oral hairy leukoplakia, thrush, severe bacterial infection, and/or 
bedridden for less than half of the last month. Stage 4 is CDC-defined AIDS and/or bedridden 
for more than half of the last month (9). Although the WHO guidelines were updated in 
November 2007 (Table 2.1), the older WHO staging criteria have been used in this study as 
they were applicable at the time patients were assessed (28). 
 
Postnatal women who had recently tested positive and had not yet had a CD4 cell count done 
or needed further management of an HIV related problem were referred to the clinic in the 
month following delivery. Most of the latter group had received single dose nevirapine during 
labour as per the previous national Prevention of Mother-to-Child Transmission (PMTCT) 
program. The aim of the PNC is to ensure comprehensive management of HIV-infected 
women. Initially once women were more than six weeks post-partum they were required to 
pay a fee as they no longer qualified for free maternal services, this was later changed as the 
PNC qualified as an antiretroviral clinic to encourage adherence to the program. Part of 
management included screening for cervical lesions by Pap smear at or after 6 weeks post 
delivery. Once the patients have received their Pap smear results and their infants HIV status 
has been determined patients are referred to an appropriate site for ongoing management. If 
they are on antiretroviral therapy they are referred to the closest adult HIV clinic for follow-up 
and if they did not qualify for antiretroviral therapy they are referred to a primary health care 
clinic for ongoing monitoring. 
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2.3 Literature review 
 
The literature search was conducted via Pubmed using the key words HIV, women, 
Papanicolaou/ Pap/ cervical smear/screening and postnatal.  
Relevant references were accessed if available via the University of the Witwatersrand 
eJournal portal. Appropriate articles cited by other authors were also reviewed.  Appropriate 
websites were also used and referenced. 
  
2.4 Data collection  
 
Data was obtained from patients’ files at the clinic as well as the laboratory which is run by 
the National Health Laboratory Services (NHLS). Information collected included age, parity, 
gravidity, date of delivery, whether they smoked, WHO Clinical Staging of HIV, CD4 cell 
counts, viral loads, treatment regimen and date of initiation, and Pap smear results. Where 
colposcopy had been performed, colposcopy biopsy results and histology from large loop 
excision of the transformation zone (LLETZ) and hysterectomy the results were collected.  
(Appendix 7.3 Data sheet) As data was retrieved from file review, certain information which is 
known to be associated with cervical abnormalities such as coitarche, number of partners and 
previous STI’s was not available.  
 
2.5 Data analysis   
 
Data was entered into Excel 2007. Variables were then coded to assist with analysis. The age 
category was divided into the following groups ≤19 years; 20-24; 25-29; 30-34; 35-39; >40 
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and unknown. The parity and gravidity categories were assigned codes corresponding to the 
actual number except for those that were unknown. Multiple CD4 cell count results were 
available for a number of patients, the most relevant being the initial count, the lowest count 
before the Pap smear and the count just preceding the Pap smear. In certain cases these were 
one in the same. The CD4 cell count category was divided as follows 0-50cells/µL; 51-
200cells/µL; 201-350cells/µL; 351-500cells/µL and ≥500cells/µL. Viral loads were not tested 
when a patient’s CD4 cell count was >200cells/µL and they therefore did not qualify for 
HAART. The viral load category was divided as follows: undetectable-40copies/ml; 41-
400copies/ml; 401-   1 000copies/ml; 1 001-10 000copies/ml; 10 001-100 000copies/ml; 
≥100 000copies/ml and not done. To work out a mean, all values recorded as <40 or 
undetectable were made ‘40’ and those that were recorded as <400 were made ‘400’. The 
values under 40 and 400copies/ml are a function of differing laboratory tests and so are 
combined and analyzed as one group at times. 
 
The South African National Antiretroviral Treatment Guidelines (39) suggest that pregnant 
women be started on stavudine (D4T), lamivudine (3TC) and nevirapine (NVP) - regimen 1b 
hence the majority of the patients in the study were on this regimen. Smaller numbers were on 
D4T, 3TC and efavirenz (EFV) – regimen 1a or D4T, 3TC and lopinavir/ritonavir (kaletra®) – 
mixed regimen. There were a few patients who were referred in from other healthcare 
providers or who were unable to take the standard regimens and were on individualized 
regimens.  
 
For statistical purposes those that were on a combination of two nucleoside reverse 
transcriptase inhibitors (NRTI) and either a non-nucleoside reverse transcriptase inhibitor 
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(NNRTI) or a protease inhibitor (PI) were considered to be on HAART. These patients were 
then analyzed together with those on the standard regimens. Some women were not on 
HAART as either they did not yet qualify or they had yet to be initiated at the time of 
performing the initial Pap smear.  
 
The World Health Organization clinical staging of HIV was recorded.  
 
The smoking habits of the women were reviewed and were classified as unknown, no 
smoking, previously and currently smoking. For statistical purposes they were grouped into 
two groups for certain tests, namely ‘never smoked’ and ‘ever smoked’.   
 
The results of the Pap smears were collected from the files and the reports checked on the 
laboratory computer system as well as checking if any subsequent tests had been done and 
recording those results. Of importance for this study was the classification on the Pap smear 
report of  no malignant cells, LGSIL, HGSIL, ASCUS and ASC-H (atypical squamous cells 
cannot exclude HGSIL). The presence or absence of endocervical cells and koilocytosis was 
also noted. Results that were classified as ‘other’ were excluded from analysis, depending on 
the statistical test used. The use of the term ‘other’ to describe one of the categories is for the 
purposes of this study only and does not reflect its use in the Bethesda classification.   
 
Where LGSIL was reported as dual pathology with ASCUS or ASC-H the result was 
considered as LGSIL for analysis. The justification being that at colposcopy, which is 
recommended for LGSIL and not always immediately for ASCUS and ASC-H in HIV positive 
women, (9) ASCUS would be more likely to be confirmed as LGSIL rather than HGSIL, and 
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although the majority of ASCUS would be normal the management would reflect the potential 
abnormality (40). 
 
The frequencies, means, medians and ranges for the data were determined. Specifically, the 
first objective to determine the number of Pap smears done, the percentage of abnormal 
results, the degree of abnormality as defined in the 2001 Bethesda classification and to review 
the management of the abnormality including the colposcopy results as well as the second 
objective to determine whether the immune status, namely the WHO clinical stage, CD4 cell 
count and viral load, correlated with the patients’ Pap smear results, were addressed using 
contingency table summaries and Pearson chi-squared tests of independence. Concerning 
objective two a one-factor analysis-of-variance (ANOVA) test and non-parametric Kruskal-
Wallis rank sum test using Box-Cox transformations were carried out. The Box-Cox 
transformations aim to create variables that are more normally distributed in order to meet the 
assumptions required for ANOVA, the transformations have no effect on the Kruskal –Wallis 
test. Objective three, to analyze patients according to the treatment received for HIV and their 
Pap smear results was investigated quantitatively using the chi-squared test. A p-value of 0.05 
was considered significant. Most of the statistical analyses were performed using the software 
package R (2006) and the remainder using Microsoft Office Excel 97-2003 Worksheet. 
Missing variables are excluded to yield a complete data set, aid analyses and help prevent bias. 
 
Regression was defined as an abnormal Pap smear result which on follow up either had 
downgraded or reverted to normal. A result was considered persistent if on follow up it had 
not changed.  Progression was defined as the follow up result having upgraded to a more 
serious grade of pathology than the initial Pap smear. 
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3.0 RESULTS 
 
3.1 Sample population 
 
A total of 324 patients attended the clinic in the study time period, of these 248 (76.5%) had a 
Pap smear and 76 (23.5%) did not. The mean age of those who did have a Pap smear was 
28.3years (data missing for one patient) with the mean parity and gravidity being 2.3 and 2.5 
respectively (data missing for 18 and 26 patients respectively). Twenty-six of the 76 (34%) 
were on HAART, the mean initial CD4 cell count being 264.1 and initial viral load 427763 
copies/ml (no result for five and 31 patients respectively). The WHO clinical stage was 
documented for 32 patients; in 44 patients (57.9%) the stage was unknown, 12 patients 
(15.8%) it was Stage 1, 4(5.3%) Stage 2, 14(1.8%) Stage 3 and 2(2.6%) Stage 4. The smoking 
habits of 27(35.5%) were not recorded while 46(60.5%) had never smoked and 3(3.9%) had 
smoked. Among the 76 women who did not have a Pap smear; one (1.3%) refused a Pap 
smear despite counseling as to its benefit, six (7.9%) no reason was specified, 22 women 
(28.9%) were referred to their local clinic for ongoing management prior to Pap smear and 47 
women (61.8%) defaulted.  
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 Figure 3.1: Flow diagram of patient group  
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Of the 248 patients who had a Pap smear 11(4.4%) were classified as ‘other’. This group 
comprised of one patient who had previously been referred to the outpatient gynaecology 
clinic and had a colposcopic biopsy which confirmed HGSIL, the original Pap result was not 
traceable, subsequent to the biopsy the Pap smear showed LGSIL. One patient needed a repeat 
Pap as the first had moderate squamous cell atypia favoring reparative and inflammatory 
changes, the repeat showed LGSIL. The remaining nine patients had insufficient ectocervical 
cells and were thus not fully representative and needed a repeat sample. Repeat Pap smears 
were found for five.  
 
3.2. Cervical smear distribution 
 
There were 131(52.8%) normal Pap smears, 64(25.8%) LGSIL, 32 (12.9%) HGSIL, 10 (4.0%) 
with ASCUS and 11 (4.4%) ‘other’. (Figure 3.2) Thus nearly half the Pap smears had some 
degree of abnormality – 47.2%. Five patients had Pap smear results which had dual diagnoses, 
three were reported as LGSIL and ASCUS and two as LGSIL and ASC-H. These were 
analyzed as part of the LGSIL group. One case of HGSIL was noted to be suspicious for 
microinvasion. This patient demised, the cause of death is unknown. One of the cases in which 
a patient had a Pap smear with a dual diagnoses – LGSIL and ASC-H – did not return for the 
result however did present to Urology the following month where a biopsy of the vagina 
showed a squamous cell carcinoma of female genital tract origin.  
 
17 
 
 Figure 3.2: Histogram of Pap smear result distribution  
 
Endocervical cells were not found in 49 of the 248 (19.8%) Pap smears. Of these 49 cases, 40 
had no malignant cells and were thus analysed as part of the ‘normal’ group and nine had 
LGSIL. The recommendation from the laboratory for the timing of a repeat Pap smear was 
immediate for the normal smears without endocervical cells and either six weeks (one case) 
six months, 12 months or 6-12 months for those with LGSIL.   
 
Koilocytosis was noted in 88 of the 248 (35.5%) Pap smears. No normal smears showed 
koilocytosis, 57/64 (89.1%) of the LGSIL, 28/32 (87.5%) of the HGSIL and 3/10 (30%) of the 
ASCUS smears.  
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Figure 3.3: Flow diagram of Pap smear management 
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Figure 3.3: Flow diagram of Pap smear management continued 
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3.3Cervical smear follow-up results 
 
3.3.1 Normal 
Repeat Pap-smears were performed in 35 women. Of these 17 were on women who had 
normal Pap smear results with inadequate endocervical component, 10 were reported as 
normal, three showed LGSIL, three had HGSIL, and one ASC-H.  Colcoscopic biopsies were 
performed for ASC-H which demonstrated viral induced cytopathic effect, and a HGSIL 
which was reported as inadequate but showed LGSIL and so went on to have a LLETZ which 
confirmed cervical intraepithelial neoplasia (CIN) 3 which was later confirmed following 
hysterectomy. The 91 normal and satisfactory smears had three repeats, all of which were 
normal again.  
 
3.3.2 LGSIL 
Among 64 smears showing LGSIL, nine had no endocervical cells, only one repeat was found 
and was normal. The 55 satisfactory smears had seven follow ups of which five were normal 
and one showed LGSIL on Pap smears while one biopsy confirmed female genital tract 
cancer.  
 
3.3.3 HGSIL 
The patients with HGSIL all had satisfactory smears. Two patients had repeat smears, one 
showed atypical cells of uncertain origin and was characterized as other – colposcopy was 
advised but no result was found. The other Pap smear showed LGSIL with no endocervical 
cells. Fourteen patients referred for colposcopy had results available; eight had a colposcopic 
directed biopsy and six a LLETZ/cone biopsy.  
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Of the biopsies, two showed LGSIL which was reconfirmed in one patient. The other six 
biopsies had HGSIL; three had a LLETZ done, which reconfirmed HGSIL but they were 
inadequate due to the lack of involvement of the endocervical margin. One of these had a 
repeat LLETZ which showed LGSIL, another had two follow up Pap smears which both 
showed HGSIL.  
 
The six LLETZ/cone biopsies all confirmed HGSIL. Four follow up Pap smears were 
performed, three had LGSIL (yet another repeat of one of these yielded a normal smear) and 
one was normal. Of the six, one had a total abdominal hysterectomy and the histology showed 
LGSIL. 
 
3.3.4 ASCUS 
The patients with ASCUS also included those with ASC-H. One patient with ASC-H had a 
LLETZ which had HGSIL focally at the endocervical margin. No other follow up results were 
found.  
 
3.3.5 Other 
The 11 Pap smears designated as ‘other’ had one colposcopic biopsy with HGSIL. A follow 
up Pap confirmed the HGSIL, but the repeat colposcopy was LGSIL. Six repeat Paps were 
found, four with LGSIL of which one went on to have colposcopy showing a HGSIL. The 
other two Paps showed one HGSIL and one normal smear.  
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3.3.6 Summary of follow-up results 
Thus among the 131 originally normal Pap smears, there were 20 patients who went on to 
have a repeat smear, of which six (30%) were abnormal. At the time of the final Pap smear, 
biopsy, LLETZ or surgery, 11 of the 20 were on ART. Four of the six patients with abnormal 
smears were on ART. Of the 64 patients with LGSIL, seven had a repeat smear – six regressed 
to normal and one showed persistent LGSIL. One smear which had a dual diagnosis, including 
ASC-H, had a biopsy which showed cancer of female genital tract origin. Of the eight follow-
ups six were on ART – five that regressed and one that stayed the same. Sixteen of the 32 
patients with HGSIL had follow up investigations and treatment. Ultimately six regressed to 
LGSIL, three to normal, six had persistent HGSIL and one joined the ‘other’ group and 
needed colposcopy. Thirteen of the 16 patients with HGSIL were on ART; seven regressed 
and six remained as HGSIL. Only one patient in the ASCUS group was followed up and was 
found to have HGSIL. This patient was not on ART. The group ‘other’ had seven follow ups 
out of 11 and finally showed two HGSIL, four LGSIL and one normal result. From the group 
of seven all but one (who had LGSIL) was on ART. A total of 52 patients had follow-up 
investigations and/or treatment, which is 21.0% of the sample. Thirty-six were on ART at the 
time of the final intervention – three for less than 12 weeks and 33 for longer. Thirty (83.3%) 
patients had full virological suppression at the time of their last intervention. (Table 3.1)  
 
3.3.7 Regression, persistence and progression 
A total of 52 patients had follow-up investigations and/or treatment, which is 21.0% of the 
sample. Thirty-six were on ART at the time of the final intervention – three for less than 12 
weeks and 33 for longer. Thirty (83.3%) patients had full virological suppression at the time of 
their last intervention. The seven from the group ‘other’ who did not have an initial Pap smear 
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with which one could make comparisons were excluded as well as those with a normal Pap 
smear which remained normal. Within the normal Pap smears 14 remained normal and six 
progressed; in the LGSIL group six regressed, one persisted and one progressed to cancer. In 
the HGSIL group nine regressed (seven following surgical treatment) and seven persisted. In 
the ASCUS group an ASC-H was confirmed as HGSIL. This gives a rate of 51.6% for 
regression, 22.6% for persistence and 25.8% for progression for the group of 31. The 23 
patients in the group of 31 who were on ART had a rate of 52.2% for regression, 30.4% for 
persistence and 17.4% for progression. The eight patients of the 31 not on ART had a rate of 
50.0% for regression, none persisted and 50.0% for progression. 
 
Twenty-two of the 31 patients whose follow-up results were looked at were on ART or for 
more than 12 weeks; 50.0% regressed, 31.8% persisted and 18.2% progressed. Nine of the 31 
were not on ART or had been on for less than 12 weeks; 55.6% regressed, none persisted and 
44.4% progressed. 
 
3.4 Cervical smear analyses 
 
3.4.1 Age 
The age range was 16 to 43 years old, with a mean of 29.47 years and median of 30 years. 
Data was missing for one patient. (Figure 3.4 and Figure 3.5) 
 
When age is cross-tabulated (Table 3.2.1) with the Pap smear results using the defined 
categories in a contingency table certain cells have a value less than five and so to avoid 
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problems with chi-squared approximation certain age categories (≤19 with 20-24 and 35-39 
with ≥40) were combined and the group ‘other’ was excluded. 
 
 The p-value for the (marginal) test of independence between the age categories and Pap smear 
categories was not significant – 0.1526. A one-factor analysis-of-variance test for equality of 
mean ages across the Pap categories shown in Table 3.2.1 yields a p-value of 0.1278 (for the 
null hypothesis of equal mean age versus the alternative hypothesis that at least one mean age 
differs). Thus as the null hypothesis is not rejected the variation in mean ages is most likely 
due to chance alone. Similarly, a non-parametric Kruskal-Wallis test for equality of median 
ages across Pap scores yields a p-value of 0.0917 (for the null hypothesis of equal median age 
versus the alternative hypothesis that at least one median age differs).  
 
If one compares the age group 20-29 versus the 30-39 year old group, a statistically significant 
difference is found (p-value is 0.009). The main differences are more normal and ‘other’ Pap 
smears among the older cohort while the ASCUS group was bigger in the younger cohort. The 
results for the LGSIL and HGSIL groups were similar. However if the ‘other’ group is not 
included in the analysis the p-value is 0.066 and thus no longer significant. (Table 3.2.2)  
 
3.4.2 Parity 
For the 215 women with data, the parity had a range of one to seven children, the mean being 
2.34 and median of two. There were 33 missing values. (Figure 3.6 and Figure 3.7)  
 
The contingency table (Table 3.3) for the Pap smear categories with the patients’ parity yields 
a p-value for the (marginal) test of independence between the two of 0.6065. Again to avoid 
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problems with chi-squared approximation, categories were combined – parity of one with two 
and four with five and six. The missing values and ‘other’ Pap smears were excluded from 
analysis. 
 
3.4.3 Gravidity 
For the 211 women with data, the gravidity had a range of one to seven, a mean of 2.56 and a 
median of two. There were 37 missing values. (Figure 3.8 and Figure 3.9) 
 
The contingency table (Table 3.4) for the Pap smear categories with the patients’ gravidity 
yields a p-value of 0.7936. To avoid problems with chi-squared approximation the extremes of 
gravidity were combined – one with two and four with five and six. The missing values and 
Pap smears classed as ‘other’ were excluded.  
 
3.4.4 WHO classification 
The raw data for the WHO classification was largely incomplete with 45.2% missing. Stage1 
accounted for 30.6% of the 248 patients, Stage 2 for 8.9%, Stage 3 for 9.3% and Stage 4 for 
6.0% of all the patients. Of the 15 patients who made up Stage 4, who by virtue of their stage 
qualify for ART according to SA Guidelines (39), 13 of them had initiated therapy whilst two 
still had not at the time of their Pap smear. Subsequently one of these patients was initiated on 
ART. The initial CD4 cell count in the patient who was not started was 246cells/µL. (Figure 
3.10 and Figure 3.11) 
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The WHO classification was compared to the Pap smears using a contingency table (Table 
3.5). Excluding the unknown values and ‘other’ Pap smears a p-value for the (marginal) test of 
independence is 0.6679.  
 
3.4.5 Smoking 
Smoking was unusual, with only five patients (2.4%) who smoked or had ever smoked and 
201 of the remaining 206 (97.6%) were non-smokers. Data was missing for 42 patients. Four 
of the five smokers had abnormal Pap smears.  
 
In this study, abnormal Pap smears are not significantly associated with smoking. A 
contingency table (Table 3.6.1) to cross-tabulate the Pap smear results against that of smoking 
and ignoring the missing values and ‘other’ Pap smears results supports that smoking is not 
significant p = 0.1875. A modified version (Table 3.6.2) in which the abnormal Pap smears 
(LGSIL, HGSIL and ASCUS) are grouped together creates a 2 by 2 table and yields a p-value 
of 0.1192 using a chi-squared test which is not statistically significant.  
 
3.4.6 CD4 cell count 
Only one patient did not have an initial CD4 cell count. The range was 3- 1193 cells/µL, with 
a mean of 257.2cells/µL and a median of 190cells/µL. (Figure 3.12) When looking at the last 
CD4 cell count prior to the Pap smear the range is 4-1193cells/µL, with a mean of 
305.6cells/µL and a median of 267cells/µL. (Figure 3.13 and Figure 3.14) 
 
The test for equality of mean response of the initial CD4 cell count and the Pap smear results 
using an ANOVA (a one-factor analysis-of-variance) test was carried out.                          
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Box-Cox transformed versions of the CD4 cell count were used to create more normally 
distributed variables in order to meet the assumptions required for ANOVA. Tests for 
homogeneity of the variances across the Pap smear results after applying the Box-Cox 
transformations all failed to reject the hypothesis of equal variances which is an assumption 
required for the one-factor ANOVA test. The p-value was significant at 0.0423. A Kruskal-
Wallis rank sum test for the equality of median response of the CD4 cell count across the Pap 
smear results was done. Box-Cox transformations have no effect on the nonparametric 
Kruskal-Wallis test. The p-value was again significant 0.0062. (Figure 3.15) Thus both the 
mean and median initial CD4 cell counts have a statistically significant relationship with the 
Pap smear results, with lower CD4 cell counts being related to worsening atypia.  
 
For both the initial CD4 cell count and the last count before the Pap smear was performed, 
contingency tables were drawn up. The single case with a missing value was combined with 
group with counts greater than or equal to 500cellsµ/L during analyses. Concerning the initial 
CD4 cell count, the p-value for the full table (Table 3.7.1) is 0.1125. If the lowest two 
categories are combined to give a category of CD4 cell counts less than 200, then the p-value 
is 0.0684. However the chi-squared approximation may be poor due to the lower than 
expected frequencies, notably in the ASCUS and ‘other’ groups. Once the ‘other’ Pap smears 
are ignored the p-value is 0.0819. Both values are approaching significance. When the CD4 
cell counts are cross-tabulated against whether or not the Pap smear was normal or abnormal 
the p-value is 0.0293.  
 
 The table (Table 3.7.2) for the CD4 closest to the Pap smear yields a p-value of 0.168. When 
the lowest two categories are combined for a CD4 cell count of less than 200 the p-value is 
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0.180. If the ‘other’ Pap smears are ignored, then the p-value is 0.114. However if the CD4 
cell count are grouped into less than 200, 201-350 and greater than 350 and analyzed against 
the Pap smear results, including the ‘other’ Pap smears, the p-value is 0.075. If the ‘other’ Pap 
smears are ignored (Table 3.7.3), the p-value is significant – 0.039. Comparing the CD4 to 
normal versus abnormal Pap smears, which was significant for the initial CD4 cell count, the 
result is not significant whether including (p = 0.063) or excluding ‘other’ (p = 0.101). 
 
In summary the contingency tables showed both significant and non-significant p- values for 
both the initial and last CD4 cell count depending on the grouping of the data. A lower CD4 
cell count was associated with an abnormal Pap smear.   
 
3.4.7 Viral load 
The initial viral load results had 49 missing values. The range was from undetectable to 
4000000copies/ml. The mean initial viral load was 122697.6copies/ml (which is a slight over 
estimation due to the rounding off of ‘<40’ and ‘<400’) and the median was 28000copies/ml. 
(Figure 3.16) The viral load before the Pap smear had 54 missing values and the range was 
from undetectable to 4000000copies/ml. The mean viral load was 41503.9copies/ml (again a 
slight over estimation) and the median was 400copies/ml. (Figure 3.17) 
 
As for the initial CD4 cell count an ANOVA test and a Kruskal-Wallis rank sum test were 
carried out on the initial viral load. The ANOVA test for equality of mean response of the 
Box-Cox transformed versions of the initial viral load across the Pap smear result categories 
was not statistically significant (p = 0.3702) and neither did the Kruskal-Wallis test on the 
median viral load play a significant role (p = 0.2891). (Figure 3.18) 
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The cross-tabulation of the Pap smear results against the initial viral loads, but ignoring the 
missing values, gives a p-value of 0.6191. Owing to the lower than expected frequencies in 
certain cells the chi-squared approximation may be poor (Table 3.8.1). If the ‘other’ Pap smear 
results are ignored then the p-value for the test of independence of classifications is 0.6723. If 
the viral load values under 1000copies/ml are combined and then reanalyzed including and 
then excluding the ‘other’ Pap smear results the p-value is 0.8242 and 0.9285 respectively. A 
similar p-value of 0.866 is obtained where the values under 400copies/ml are combined and 
the missing and ‘other’ results are ignored.  
 
When cross-tabulating the Pap smear results against the last viral load before the Pap smear, 
but ignoring the missing values, one gets a p-value of 0.841. Due to the lower than expected 
frequencies in certain cells (Table 3.8.2) the chi-squared approximation may be poor. If the 
‘other’ Pap smear results are ignored then the p-value for the test of independence of 
classifications is 0.699. If the viral load values under 1000copies/ml are combined and 
reanalyzed including and then excluding the ‘other’ Pap smear results the p-value is 0.955 and 
0.862 respectively. As above a p-value of 0.920 is obtained where the values under 
400copies/ml are combined and the missing and ‘other’ results are ignored. 
 
In summary neither the initial nor the last viral load showed a statistically significant 
relationship with the Pap smears results. 
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3.4.8 ART 
Prior to their first Pap smear, 139 women (56.0%) had initiated ART. Of the 109 women 
(44.0%) who had not, 20 were eligible and ten of these subsequently initiated therapy. A 
further three patients had CD4 cell counts which decreased later and were thus eligible and 
then initiated treatment, bringing the total of those starting after the initial Pap smear to 13. In 
the group of 139 women, 135 were on HAART and four were on individualized regimens. By 
the end of the study time period a total of 152 women (61.3%) were on therapy. One hundred 
and forty-eight were on HAART and four on individualized regimens.  
 
The Pap smear results were cross-tabulated with the ART usage of the patients prior to the Pap 
smear. The p-value for the full-table (Table 3.9.1) is 0.0597, with possible problems with chi-
squared approximation. The p-value if the ‘other’ group is excluded is 0.0475, with possible 
problems with chi-squared approximation. If the table is collapsed (Table 3.9.2) to compare 
ART usage versus no ART usage before the Pap smear both including and then excluding the 
‘other’ group then the p- values are 0.0874 and 0.0788 respectively. 
 
A 2 by 2 table (Table 3.9.3) comparing ART use versus no ART’s and normal versus 
abnormal Pap smears gives a statistically significant p-value of 0.0110. However recognizing 
the fact that different patients had been on ART’s for different lengths of time, the table (Table 
3.9.4) was recalculated. The ART category was re-divided into two groups, firstly no ART use 
and those on for less than 12 weeks versus those who had been on for 12 weeks or more.  
Viral suppression to less than 500copies/ml would be expected by 8 to 16 weeks (9). The p-
value was 0.067 which was no longer statistically significant.  
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The data was again refined (Table 3.9.5) by removing those not on ART’s and who were not 
eligible i.e. a CD4≥200cells/µL. The p-value was not statistically significant at 0.424. It 
remained not significant (0.342) if the abnormal Pap smears were returned to their original 
diagnoses (Table 3.9.6). 
The data was tabulated (Table 3.9.7) in order to characterize the normal versus abnormal Pap 
smear results by the use of ART’s and duration of treatment as well as by their immunological 
status prior to the Pap smear being performed. 
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4.0 DISCUSSION 
 
4.1 Summary of the main results 
 
4.1.1 Study objective one 
Among 324 women who attended the post natal clinic, 248 (76.5%) had a Pap smear, 22 
(6.8%) were referred to their local clinic for a Pap smear and 47 (14.5%) defaulted their 
follow-up appointments. Only one woman (0.003%) refused a Pap and in 6 (1.9%) no reason 
was found for it not being done.  As a health intervention the postnatal clinic was successful in 
screening over 75% of these high risk women for cancer of the cervix. However to ensure 
wider coverage, monitoring those who were down-referred for Pap smears and ensuring those 
in the referral areas are up-referred appropriately would improve the impact of the program. 
The expansion of this initiative more broadly would also be of great public health benefit in 
view of the serious consequences of cancer of the cervix and the high prevalence among post 
natal HIV infected women of cervical smear abnormalities.   
 
 Of the 248 patients 47.2% had abnormal pap smears, 25.8% had LGSIL, 12.9% had HGSIL 
and 4.0% had ASCUS. Of further importance were the facts that 80.2% of the Pap smears 
were satisfactory for evaluation and 35.5% were affected by koilocytosis.  
 
In terms of the management of the Pap smear results (Figure 3.3) there were a few deviations 
from the standard. Regarding the three normal and satisfactory Pap smears that were repeated, 
the time interval was very short. It is possible that when the clinician reviewing the patient 
looked for a result and nothing was initially found, the test was repeated.  
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Unfortunately there was not a protocol that consistently recommended the follow-up of 
patients with LGSIL, namely six weeks (one case), six months, 12 months or 6-12 months. 
There were also five patients where colposcopy was suggested, however no such results were 
found although one did have a normal repeat Pap smear six months later. Patients with HGSIL 
were all referred for colposcopy at which either a biopsy was taken or a see and treat approach 
was adopted using LLETZ at the clinicians’ discretion. One deviation from standard practice 
was noted in a patient  who after a LLETZ showing HGSIL went on to have a follow- up Pap 
smear which again had HGSIL, and again repeated six months later, the  result of which 
remained unchanged. In the ‘other’ group a patient had a colposcopic biopsy which showed 
HGSIL the Pap smear was again repeated six months later which also showed HGSIL. After 
three months she had a colposcopy and this confirmed the presence of LGSIL.  These patients 
needed a definitive excisional procedure to prevent the occurrence of cervical cancer. 
Increased awareness of the correct management of abnormal cytology and histology results is 
needed. A thorough review of a patient’s history and previous investigations as well as a 
reliable method of retrieving results would help prevent unnecessary duplication of 
investigations and delay in appropriate management. 
 
4.1.2 Study objective two 
The second objective was to correlate the immune status of the patient with their Pap smear 
result. There was no statistically significant association between the WHO classification and 
the Pap smear results. Concerning the CD4 cell count the p-value approaches significance 
when one compares the CD4 cell count categories with the Pap smear results. Once the CD4 
cell count categories are combined such that they reflect the level at which ART would be 
initiated (<200cells/ml in the South Africa, <350cells/ml in well resourced settings) then the 
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p-value is significant at 0.039. The analysis of the viral load against the Pap smear did not 
yield a significant p-value.  
 
4.1.3 Study objective three 
The third objective concerning the use of ART and the patients’ Pap smear results yields 
significant p-values on the data (p-value 0.0475). ART use is associated with abnormal Pap 
smear results reflecting the poor immune function of the patients who were initiated. However 
once it is refined by excluding those not on ART and not eligible - so that the comparison is 
between those not on ART and eligible or on ART for less than 12 weeks, versus those on for 
more than 12 weeks the p-value is not significant (0.424). 
 
The follow-up results had a rate of 51.6% for regression, 22.6% for persistence and 25.8% for 
progression for the available group of 31. Of the twenty-two patients on ART or for more than 
12 weeks; 50.0% regressed, 31.8% persisted and 18.2% progressed. Nine of the 31 were not 
on ART or had been on for less than 12 weeks; 55.6% regressed, none persisted and 44.4% 
progressed. . While these patients were not prospectively randomized and the follow-up results 
only represent a biased 21.0% of the sample, they do appear to suggest that the use of ART is 
beneficial. However the numbers are small especially of the no ART group.  
 
4.2 Limitations  
 
The 248 cases that were analyzed reflect two different data generating mechanisms, those that 
were being followed up having been initiated on ART’s during their pregnancy and those that 
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were referred post-delivery for further management of conditions relating to their positive 
status and who were not necessarily on ART’s. 
 
 Thus the group is not a random sample of the general population, and the results obtained 
cannot be generalized as such. The population is however reflective of the aims of the 
postnatal clinic itself and results may be generalizable to interventions proposed to similar 
groups of women. .  
 
The limitations of this study are largely due to its retrospective nature. Certain demographic 
variables were not recorded and the definitions used may have differed between health care 
workers. Of concern, results for the gravidity appeared to be reported inconsistently between 
health care workers, and may not reflect a true result.  
 
It must be noted that except for the use of ART’s, every other data set had a variable number 
of missing values. This is a known weakness of retrospective studies. When gathering the 
results from the laboratory computer system, it was frequently necessary to search using 
different combinations of the name, surname, hospital number and birth date to find all the 
relevant results. Frequently names were misspelled or hospital numbers incorrectly recorded. 
As far as possible the final body of data was as accurate as possible, acknowledging the 
inherent problems of the system.  
 
 Follow-up was not consistent and only results that were available retrospectively were 
included. There is no information as to why those who were supposed to have repeat 
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investigations did not return. There is little bias in terms of the sample as every patient who 
had a Pap smear in the time frame was included.  
 
The accuracy of a retrospective study can be improved in a number of ways. Standardized 
clerking forms, especially if they were computerized would go a long way to improving data 
collection. Staff training in the field of interest, its management and appropriate referrals also 
contributes. Compliance can be improved with active follow-up and reminders to patients via 
cellular phone messaging. 
 
4.3 Interpretation  
 
The primary aim of the study has been fulfilled in that the range and rate of Pap smear 
abnormalities for our post partum HIV positive women attending the post-natal clinic has been 
described. Through rigorous follow-up 76.5% of the attendees were screened for cancer of the 
cervix. . In 2007 only 22% of women who needed a screening Pap smear received one in 
South Africa’s cancer of the cervix screening programme (41). 
 
The study was then looked at in light of the available literature. (Table 1.1) The average 
sample size from the literature review was 223 (range 49 to 467) women, so the 248 in this 
study compared favorably. The mean age of the sample was 29.47 years and the median was 
30 years. In the literature all but four had means or medians slightly greater than ours, the 
oldest being 36 years. The youngest was from the Zimbabwean study at 28.1 years (mean) (20). 
The median CD4 was available from eight of the studies and was generally higher than our 
37 
 
190cells/µL, only two were lower – 160 and 165cells/µL although both had higher ART use 
than our 55.8% at 100% and 76, 3% respectively.   
 
The result of 52.8% normal Pap smears is lower than the majority of studies identified in the 
literature review.  Five studies were lower, including both South African studies, which had 
rates of 45% (22) and 50% (10). Moodley however had a very large proportion of ASCUS in 
their sample – 20.5% versus our 4.0%. Overall then 47.2% of this sample had an abnormality 
that is in contrast to prevalence at about 10 % in the general American population (42).   
 
The study had a rate of 25.8% LGSIL which was the third highest in comparison with the 
literature. The study by Heard in 1998 being the highest (43%), their median CD4 cell count 
was lower than this study though – 160cells/µL versus 190cells/µL (23). The HGSIL rate of 
12.9% was fifth highest with the rest being less than 8%. The reporting of ASCUS varied 
widely with five studies not reporting it all and a wide range amongst those that did (0.4-
20.7%), this study’s finding was on the lower end with 4.0%. None of the studies mentioned 
had a default category of ‘other’ as this study did which mainly included those with no 
ectocervix represented for interpretation.  
 
In keeping with the literature the abnormal Pap smears tended to have lower mean CD4 cell 
counts than the normal Pap smears (43). The results of the contingency tables and the tests for 
equality of mean response looking at the viral load and Pap smears did not find any significant 
association which is in contrast to the literature where higher viral loads were associated with 
a greater risk of abnormality (15). Possibly this study was not powered sufficiently to detect an 
association. 
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Neither the WHO Staging for HIV disease nor the use of cigarettes yielded a significant p-
value, although the results regarding the staging were limited by a large amount of missing 
data and that of smoking by the small numbers. The literature does however note the link 
between smoking and abnormal Pap smears but no association has been noted between the 
WHO stage and abnormal Pap smears. 
 
The use of ART versus the Pap smear results produced some statistically significant p-values 
which suggested that there was an association between the use of ART and the risk of an 
abnormal smear; however once confounding factors were controlled for this association is lost 
and suggests that ART usage is a marker of  immune status/advanced disease.  
 
4.4 Generalisability of results 
 
While this study specifically looked at postnatal HIV infected women predominantly with 
advanced HIV disease, the findings can still be generalized to similar groups of women 
particularly those with advanced disease and those found at ART roll-out sites. 
 
4.5 Summary of the implications for clinical practice and research 
 
With an estimated 2.8 million women living with HIV in South Africa in 2007 according to 
the Department of Health’s National HIV and Syphilis Prevalence Survey (1) the implication of 
this study is that if 47.1% were to have a cervical smear abnormality as they became 
progressively immunocompromised then our gynaecological services would be placed under 
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severe strain. As can be seen in the flow diagram on those patients that had follow- up, often 
multiple visits are required to health services in order to manage the patient appropriately. 
 
Knowing the enormity of the problem, implementation of a national screening programme for 
women in general with a special focus on those that are HIV sero-positive is needed. It is 
important to note that the mean age in this study was 29.47years which is almost the 
recommended age for commencing screening in South Africa. This finding suggests that 
screening should be started earlier and possibly more frequently. Protocols for the 
management of Pap smear abnormalities in HIV sero-positive women need to be standardized 
and added to those that already exist. Once this is done research into the effectiveness of the 
programme can be done and improvements made. The HPV vaccines and HPV testing are yet 
to be widely used within the South African context and their addition to a government funded 
initiative against cervical pathology will be some time in coming. 
 
5.0 CONCLUSION 
 
The rates of cervical abnormality in HIV sero-positive patients attending the Johannesburg 
Hospital postnatal clinic are much higher (47, 1%) than would be expected in the general 
population, with a significant portion requiring follow-up investigation and management. It is 
however preferable to deal with the problem comprehensively during the screening phase 
rather than trying to manage a potential increase in cervical cancer cases. 
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6.0 FUNDING 
 
This study had no direct costs associated with it besides printing and this was borne by the 
researcher. 
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7.0 APPENDIX 
 
7.1 Tables 
 
Table 2.1: Modified WHO Staging System for HIV infection and disease in adults and 
adolescents after the WHO 2007 guidelines 
 
Reproduced with the permission of Dr V. Black 
Stage 1 Asymptomatic 
Persistent generalized lymphadenopathy 
Stage 2 Unexplained weight loss < 10% body weight 
Recurrent respiratory tract infections 
Herpes Zoster 
Angular chelitis 
Skin lesions 
Oral ulceration 
Stage 3 Unexplained weight loss > 10% body weight 
Chronic diarrhea > 1 month 
Persistent fever > 37.5oC > 1 month 
Oral candidiasis, leukoplakia 
Pulmonary tuberculosis 
Severe bacterial infections 
Ulcerative stomatitis, gingivitis, periodontitis 
Unexplained anaemia, neutropenia, thrombocytopenia 
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Stage 4 Wasting syndrome: weight loss > 10% plus either chronic diarrhea, prolonged fever 1 
> month or chronic weakness 
Pneumocystis jeroveci (previously carinii) 
Chronic herpes infection 
Oesophageal candidiasis 
Extra pulmonary tuberculosis 
Non tuberculosis mycobacteria infection 
Recurrent infections or septicaemia 
Cytomegalovirus retinitis 
HIV encephalopathy 
Cryptococcal meningitis 
Disseminated mycosis 
Kaposi’s sarcoma 
Invasive cervical cancer 
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Table 3.1: ART usage amongst patients with follow-up results 
Initial Pap 
Result 
Final Pap/Biopsy or 
LLETZ/TAH 
Repeat 
Result 
No 
ART* 
ART 
 <12w* 
ART 
>12w* 
Total 
Normal Pap Normal 7 1 6 14 
 ″ LGSIL 0 0 2 2 
 ″ HGSIL 1 0 1 2 
 ″ other 1 0 0 1 
 TAH CIN 3 0 (9) 0 (1) 1 (10) 1(20)
LGSIL Pap Normal 1 1 4 6 
 ″ LGSIL 0  0  1  1  
 Biopsy Cancer 1 (2) 0 (1) 0 (5) 1 (8) 
HGSIL Pap/Biopsy LGSIL 2 0 0 2 
 ″ HGSIL 0 0 3 3 
 ″ other 1 0 0 1 
 LLETZ/TAH Normal 0 0 3 3 
 ″ LGSIL 0 0 4 4 
 ″ HGSIL 0 (3) 0 (0) 3 (13) 3(16)
ASCUS LLETZ HGSIL 1 (1) 0 (0) 0 (0) 1(1) 
Other Pap/Biopsy Normal 0 1 0 1 
 ″ LGSIL 1 0 3 4 
 ″ HGSIL 0 (1) 0 (1) 2 (5) 2 (7) 
TOTALS   16 3 33 52 
*refers to ART usage at the time of the final result  
 
Table 3.2.1: Pap smear results versus age categories  
 Pap Normal LGSIL HGSIL ASCUS other Total 
Age        
Missing  1 0 0 0 0 1 
≤19  2 0 1 0 0 3 
20-24  14 10 6 1 0 31 
25-29  43 25 9 7 1 85 
30-34  55 20 14 0 7 96 
35-39  13 8 2 1 2 26 
≥40  3 1 0 1 1 5 
Total  131 64 32 10 11 248 
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Table 3.2.2: Pap smear results versus age selected categories 
 
 Pap Normal LGSIL HGSIL ASCUS other Total 
Age        
20-29 
(%) 
 57 
(49.1) 
35 
(30.2) 
15 
(12.9) 
8  
(6.9) 
1 
(0.9) 
116 
30-39 
(%) 
 68 
(55.7) 
28 
(30.0) 
16 
(13.1) 
1 
(0.8) 
9 
(7.4) 
122 
Total  125 63 31 9 10 238 
 
Table 3.3: Pap smear results versus parity 
 Pap Normal LGSIL HGSIL ASCUS other Total 
Parity        
Missing  19 8 0 3 3 33 
1  19 9 4 2 1 35 
2  55 25 16 2 3 101 
3  26 16 11 3 3 59 
4  9 4 1 0 0 14 
5  3 1 0 0 0 4 
6  0 1 0 0 0 1 
7  0 0 0 0 1 1 
Total  131 64 32 10 11 248 
 
Table 3.4: Pap smear results versus gravidity 
 Pap Normal LGSIL HGSIL ASCUS other Total 
Gravidity        
Missing  23 8 0 3 3 37 
1  14 6 3 2 1 26 
2  50 24 12 1 1 88 
3  26 18 11 3 5 63 
4  13 5 5 1 0 24 
5  4 2 1 0 0 7 
6  1 1 0 0 0 2 
7  0 0 0 0 1 1 
Total  131 64 32 10 11 248 
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Table 3.5: Pap smear results versus WHO clinical stages 
 Pap Normal LGSIL HGSIL ASCUS other Total 
WHO        
Missing  59 28 18 1 6 112 
1  39 23 6 6 2 76 
2  10 6 4 1 1 22 
3  15 4 1 1 2 23 
4  8 3 3 1 0 15 
Total  131 64 32 10 11 248 
 
Table 3.6.1: Pap smear results versus smoking 
 Pap Normal LGSIL HGSIL ASCUS other Total 
Smoking        
Missing  23 11 2 2 4 42 
Never smoked  107 51 29 7 7 201 
Ever smoked  1 2 1 1 0 5 
Total  131 64 32 10 11 248 
 
Table 3.6.2: Pap smear results (collapsed) versus smoking 
 Pap Normal Abnormal Total
Smoking     
Never smoked  107 87 194 
Ever smoked  1 4 5 
Total  108 91 199 
 
Table 3.7.1: Pap smear results versus first CD4 cell count results 
 Pap Normal LGSIL HGSIL ASCUS other Total
CD4 cell count (cells/µL)        
0-50  8 4 3 0 0 15 
51-200  49 36 17 5 9 116 
201-350  35 16 5 1 1 58 
351-500  19 2 4 3 0 28 
≥500  20 5 3 1 1 30 
Missing  0 1 0 0 0 1 
Total  131 64 32 10 11 248 
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Table 3.7.2: Pap smear results versus last CD4 cell count prior to Pap smear results 
 Pap Normal LGSIL HGSIL ASCUS other Total
CD4 cell count (cells/µL)        
0-50  7 1 1 0 0 9 
51-200  35 32 9 1 5 82 
201-350  40 19 12 4 4 79 
351-500  21 5 5 3 0 34 
≥500  28 6 5 2 2 43 
Missing  0 1 0 0 0 1 
Total  131 64 32 10 11 248 
 
Table 3.7.3: Pap smear results versus last CD4 cell count (collapsed) prior to Pap smear 
results  
 Pap Normal LGSIL HGSIL ASCUS Total
CD4 cell count (cells/µL)       
0-200  42 33 10 1 86 
201-350  40 19 12 4 75 
≥351  49 12 10 5 76 
Total  131 64 32 10 237 
 
Table 3.8.1: Pap smear results versus initial viral load 
 Pap Normal LGSIL HGSIL ASCUS other Total 
VL (copies/ml)        
Missing  34 8 5 1 1 49 
Undetectable-40  5 3 0 1 1 10 
41-400  6 3 5 1 0 15 
401-1000  5 2 0 0 0 7 
1001-10000  20 14 4 3 0 41 
10001-100000  38 21 9 3 5 76 
≥100000  23 13 9 1 4 50 
Total  131 64 32 10 11 248 
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Table 3.8.2: Pap smear results versus viral load before Pap smear 
 Pap Normal LGSIL HGSIL ASCUS other Total 
VL (copies/ml)        
Missing  38 9 5 1 1 54 
Undetectable-40  16 14 6 4 2 42 
41-400  35 15 10 1 5 66 
401-1000  7 6 3 0 0 16 
1001-10000  13 9 4 3 1 30 
10001-100000  13 8 2 1 1 25 
≥100000  9 3 2 0 1 15 
Total  131 64 32 10 11 248 
 
Table 3.9.1: Pap smear results versus ART usage before the Pap smear 
 Pap Normal LGSIL HGSIL ASCUS other Total 
ART (before 
Pap  smear) 
       
Nil  68 25 10 3 3 109 
Regimen 1a & b  61 36 19 7 7 130 
Other  2 0 2 0 0 4 
Regimen 2  0 3 1 0 1 5 
Total  131 64 32 10 11 248 
 
Table 3.9.2 Pap smear versus ART usage (collapsed) before the Pap smear 
 Pap Normal LGSIL HGSIL ASCUS other Total 
ART (before 
Pap  smear) 
       
No ART’s  68 25 10 3 3 109 
ART   63 39 22 7 8 139 
Total  131 64 32 10 11 248 
 
Table 3.9.3 Pap smear results (collapsed) versus ART usage (collapsed) before the Pap smear 
 Pap Normal Abnormal Total 
ART (before 
Pap smear) 
    
No ART’s  68 41 109 
ART’s  63 76 139 
Total  131 117 248 
 
48 
 
Table 3.9.4: Pap smear results (collapsed) versus ART usage duration before the Pap smear 
 Pap Normal Abnormal Total 
ART (before 
Pap smear) 
    
No ART’s or 
<12w use 
 79 57 136 
ART’s for 
≥12w 
 52 60 112 
Total  131 117 248 
 
Table 3.9.5: Pap smear results (collapsed) versus ART usage duration or eligibility before the 
Pap smear 
 Pap Normal Abnormal Total 
ART (before 
Pap smear) 
    
No ART’s but 
eligible or <12w 
use 
 19 29 48 
ART’s for 
≥12w 
 52 60 108 
Total  71 89 156 
 
Table 3.9.6: Pap smear results versus ART usage duration or eligibility before the Pap smear 
 Pap Normal LGSIL HGSIL ASCUS other Total 
ART (before 
Pap  smear) 
       
No ART’s but 
eligible or <12w 
use 
 19 17 9 0 3 48 
ART’s for 
≥12w  
 52 31 16 7 6 112 
Total  71 48 25 7 9 160 
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Table 3.9.7: Distribution of Pap smear results according to time on ART’s and immunological 
status 
Patients Pap smear result ART usage ART duration CD4 (cells/µL) VL (copies/ml)
248 patients 131 normal 63 ARTs 11 < 12w 10 < 200 4 ≤ 400 
     6 > 400 
    1 ≥ 200 1 ≤ 400 
   52 ≥ 12w 24 < 200 16 ≤ 400 
     7 > 400 
     1 Missing 
    28 ≥ 200 24 ≤ 400 
     4 > 400 
  68 no ART’s  8 < 200 2 ≤ 400 
     3 > 400 
     3 Missing 
    60 ≥ 200 4 ≤ 400 
     22 > 400 
     34 Missing 
 117 abnormal 75 ART’s 15 < 12w 11 < 200 3 ≤ 400 
     8 > 400 
    4 ≥ 200 4 ≤ 400 
   60 ≥ 12w 27 < 200 17 ≤ 400 
     10 > 400 
    33 ≥ 200 29 ≤ 400 
     4 > 400 
  42 no ART’s  11 < 200 1 ≤ 400 
     8 > 400 
     2 Missing 
    31 ≥ 200 3 ≤ 400 
     14 > 400 
     14 Missing 
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7.2 Figures 
 
 
Figure 3.4 
 
 
Figure 3.5 
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Figure 3.6 
 
 
 
 
 
Figure 3.7 
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Figure 3.8 
 
 
 
 
Figure 3.9 
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Figure 3.10 
 
 
 
 
 
 
Figure 3.11 
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Figure 3.12 
 
 
 
 
 
Figure 3.13                            
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 A = initial CD4 cell count   B= last CD4 cell count before Pap smear 
Figure 3.14 
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Figure 3.15 Boxplot of CD40.3307  versus Pap smear result 
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 Figure 3.16 
 
 
Figure 3.17 
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Figure 3.18  Boxplot of VL0.1115  versus Pap smear result 
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7.3 Data sheet 
Study number  Age  
Parity  Gravidity  
Date of delivery  HIV test date  
CD4 cell count date(1)  CD4 result (1)  
CD4 cell count date (2)  CD4 result (2)  
CD4 cell count date (3)  CD4 result (3)  
CD4 cell count date (4)  CD4 result (4)  
CD4 cell count date (5)  CD4 result (5)  
CD4 cell count date (6)  CD4 result (6)  
CD4 cell count date (7)  CD4 result (7)  
CD4 cell count date (8)  CD4 result (8)  
CD4 cell count date (9)  CD4 result (9)  
CD4cell count date(10)  CD4 result (10)  
CD4cell count date(11)  CD4 result (11)  
VL date (1)  VL result (1)  
VL date (2)  VL result (2)  
VL date (3)  VL result (3)  
VL date (4)  VL result (4)  
VL date (5)  VL result (5)  
VL date (6)  VL result (6)  
VL date (7)  VL result (7)  
VL date (8)  VL result (8)  
VL date (9)  VL result (9)  
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VL date (10)  VL result (10)  
VL date (11)  VL result (11)  
VL date (12)  VL result (12)  
VL date (13)  VL result (13)  
ARV initiation date  ARV regimen  
ARV amendment date   Amended regimen (1)  
ARV amendment date  Amended regimen (2)  
ARV amendment date  Amended regimen (3)  
ARV amendment date  Amended regimen (4)  
WHO Stage  Other illnesses  
Habits    
Cervical smear date (1)  Lab no. (1)  
Result  
Cervical smear date (2)  Lab no. (2)  
Result  
Cervical smear date (3)  Lab no. (3)  
Result  
Cervical smear date (4)  Lab no. (4)  
Result  
Cervical smear date (5)  Lab no. (5)  
Result  
Colposcopy date (1)  Lab no.(1)  
Result    
Colposcopy date (2)  Lab no. (2)  
Result    
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LLETZ date   Lab no.   
Result    
Surgery date  Lab no.  
Result    
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